17. Trade and other receivables and other current assets
|
31 December |
|
|---|---|---|
(thousands of €) |
2019 |
2018 |
Trade receivables |
39,603 |
9,206 |
Prepayments |
292 |
142 |
Other receivables |
14,114 |
9,261 |
Trade and other receivables |
54,009 |
18,609 |
Inventories |
255 |
276 |
Accrued income |
4,443 |
3,863 |
Deferred charges |
4,439 |
4,104 |
Other current assets |
9,138 |
8,244 |
Total trade and other receivables & other current assets |
63,147 |
26,852 |
Trade and other receivables increased due to the outstanding receivable as at 31 December 2019 of €17.8 million ($20 million) on Gilead related to a milestone for NDA filing in the United States related to filgotinib and the 50% cost reimbursement for GLPG1690 (€13.4 million) invoiced to Gilead under the cost sharing mechanism.
We consider that the carrying amount of trade and other receivables approximates their fair value.
The other current assets mainly included accrued income from subsidy projects and deferred charges.
On 31 December 2019, we did not have any provision for expected credit losses.